One-Time immune boost for ARID1A-Mutant cancers?

NCT ID NCT06824363

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This early-phase trial is testing whether a single dose of two immunotherapy drugs (tremelimumab and durvalumab) can increase cancer-fighting immune cells inside tumors. It includes 34 people with untreated, non-metastatic stomach or esophageal cancers that have an ARID1A gene mutation. The main goal is to see if the treatment is feasible and changes the tumor's immune environment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tremelimumab and Durvalumab (two immunotherapy drugs given as a single dose)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat stomach and esophageal cancers that have a specific genetic mutation (ARID1A).
What could go wrong
This is a very early, small proof-of-principle study with only 34 people. It is designed to see if the drugs increase immune cells in the tumor, not yet to prove they shrink tumors or extend life. Immune checkpoint inhibitors can cause serious immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Chao Family Comprehensive Cancer Center, University of California, Irvine

    RECRUITING

    Orange, California, 92868, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.